Table 1.

Clinical characteristics and outcome of 732 cases of de novo DLBCL with R-CHOP regimen

	All patients (n=732)	EBV+ (n=28)	EBV− (n=675)	P value
Median age	63.0 (16.0–95.0)	60.5 (35.0–86.0)	63.5 (16.0–95.0)	0.426
Gender
Male	421 (57.5%)	18 (64.3%)	387 (57.3%)
Female	311 (42.5%)	10 (35.7%)	288 (42.7%)	0.560
Age
≤60	313 (42.8%)	14 (50.0%)	283 (41.9%)
>60	419 (57.2%)	14 (50.0%)	392 (58.1%)	0.438
B symptoms
Absence	423 (64.4%)	14 (58.3%)	397 (64.8%)
Presence	234 (35.6%)	10 (41.7%)	216 (35.2%)	0.521
ECOG performance status
<2	529 (84.5%)	19 (73.1%)	488 (85.2%)
≥2	97 (15.5%)	7 (26.9%)	85 (14.8%)	0.099
Stage
I–II	329 (46.4%)	11 (39.3%)	305 (46.8%)
III–IV	380 (53.6%)	17 (60.7%)	347 (53.2%)	0.562
Extranodal sites
<2	529 (79.0%)	22 (84.6%)	487 (79.1%)
≥2	141 (21.0%)	4 (15.4%)	129 (20.9%)	0.626
LDH
Normal	246 (37.7%)	8 (29.6%)	228 (38.1%)
Elevated	407 (62.3%)	19 (70.4%)	371 (61.9%)	0.423
IPI score
0–2	401 (59.3%)	16 (57.1%)	368 (59.4%)
3 to 5	275 (40.7%)	12 (42.9%)	252 (40.6%)	0.846
Tumor size (cm)
<6	354 (64.1%)	10 (58.8%)	335 (64.7%)
≤6	198 (35.9%)	7 (41.2%)	183 (35.3%)	0.615
Treatment response
CR/PR	612 (89.2%)	24 (88.9%)	562 (89.2%)
No response	74 (10.8%)	3 (11.1%)	68 (10.8%)	1.000

ECOG; Eastern Cooperative Oncology Group, IPI; International Prognostic Index, CR; Complete Remission, PR; Partial Remission